Ginkgo Bioworks Holdings, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jason Kelly
- Full Time Employees
- 485
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 27 Drydock Avenue Boston MA United States of America 02210
- IPO Date
- Apr 19, 2021
- CIK
- 0001830214
- Website
- ginkgo.bio
- Similar Companies
- Business
- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) operates as a leading synthetic biology company that develops a cell programming platform enabling customers to engineer organisms for applications across pharmaceuticals, biotechnology, agriculture, industrial biotech, food and nutrition, consumer products, and biosecurity; its core offerings include cell engineering research and development solutions such as functional genomics, antibody developability services, artificial intelligence models, reconfigurable automation systems, strain improvement for optimized microorganism production, Ginkgo Enzyme Services encompassing novel enzyme discovery, high-expression host strains like methanol-free Pichia pastoris and low-viscosity Aspergillus niger, fermentation process development with Ambr 250 bioreactors, and manufacturing scale-up up to 3,000L capacity, as well as biosecurity services through Canopy for biomonitoring and genomic data generation and Horizon for digital surveillance and biothreat detection. Founded in 2008 and headquartered at 27 Drydock Avenue in Boston, Massachusetts, the company serves diverse industries including government and defense via its two main segments of Cell Engineering and Biosecurity, with operations centered in the United States and facilities supporting global partnerships. Recent developments include the launch of Ginkgo Enzyme Services to advance enzyme R&D for pharmaceuticals, diagnostics, food, agriculture, and materials through ultra-high-throughput screening and machine learning-guided protein design; a multi-year extension of its strategic partnership with Bayer, originally established in 2017, to develop microbial nitrogen fixation, biological crop protection, and carbon sequestration solutions for sustainable agriculture, with Bayer retaining commercialization rights; and prior acquisitions such as FGen AG's screening platform in 2022 and Reverie Labs platform in 2024 to enhance its bioengineering capabilities.
Ginkgo Bioworks Q2 Earnings Call Highlights
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
UW Credit Union Selects DNA from Fiserv to Power its Next Stage of Growth
Kane Biotech Announces Engagement of DNA Advisors
Core DNA: Coreweave and Nebius Couldn't Be More Different and Why It Matters
Caxton Associates LLP Sells 103,802 Shares of Ginkgo Bioworks Holdings, Inc. $DNA
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think
FTAI Aviation: Innovation Is Their DNA
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
DNA X, Inc. Reports First Quarter 2026 Financial Results
DNA Finland Extends Fiber-Grade Connectivity to Lower-Density MDUs with Harmonic
Ginkgo Bioworks: Another Lost Year
The $59B Quiet Shift Reshaping How Patients Access Care
Lotus Unveils Focus 2030 – Reinforcing Brand DNA with an All-New Hybrid-V8 Supercar